Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure […]

Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different

Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,

A comprehensive framework covering due diligence, KPI architecture, IP asset valuation, technology roadmaps, and strategic governance across the full drug

When generic competition arrives, it arrives fast. Within the first 12 months of a major brand losing exclusivity, generic entrants

I. Executive Summary and Investment Thesis The Core Problem The generic drug industry saves the U.S. healthcare system roughly $216

Partnering with a Contract Development and Manufacturing Organization (CDMO) is no longer a simple procurement exercise. It is a fundamental

1. Executive Summary and Key Takeaways The FDA’s Product-Specific Guidance (PSG) program is now the most consequential publicly available dataset

The complete 2025 playbook for generic drug development strategy: Paragraph IV mechanics, complex generics IP moats, biosimilar development roadmaps, IRA